Jiangsu Hengrui Medicine
600276.SS
#399
Rank
A$86.68 B
Marketcap
A$13.06
Share price
1.42%
Change (1 day)
27.25%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): A$0.19

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.19. In 2024 the company made an earnings per share (EPS) of A$0.21 an increase over its 2023 EPS that were of A$0.15.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.19-7.24%
2024A$0.2142.43%
2023A$0.158.77%
2022A$0.13-20.62%
2021A$0.17-26.59%
2020A$0.2327.24%
2019A$0.1828.41%
2018A$0.1420.04%
2017A$0.1231.21%
2016A$0.0891211.46%
2015A$0.0799636.27%
2014A$0.0586819.77%
2013A$0.0489918.05%
2012A$0.0415023.9%
2011A$0.0335026.9%
2010A$0.0264012.37%
2009A$0.0234956.6%
2008A$0.015009.18%
2007A$0.01374114.48%
2006A$0.00640664.83%
2005A$0.00388635.55%
2004A$0.00286729.73%
2003A$0.00221019.86%
2002A$0.001844-2.71%
2001A$0.0018951.02%
2000A$0.001876